The Molecular Glue Drug Development Summit returns to Boston with fresh insights and opportunities! With powerhouse ...

Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...

Novartis has agreed to pay Monte Rosa $150 million upfront ... Jefferies London Healthcare Conference (London, UK) – November 19, 2024. A webcast of the fireside chat will be accessible via the ...

Seaport Therapeutics (“Seaport or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...

A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...

SLE is a chronic and complex heterogeneous autoimmune disease in which the immune system dysfunctions and inappropriately ...

The Ministry of Industry and Trade yesterday hosted a conference, themed  “Export to the UK market - strategies and ways to ...

Healthcare is possibly the most overlooked of all the mega-trends. But this may leave investors with more opportunities once ...

European equities dipped on Tuesday as earnings from heavyweights BP Plc and Novartis AG failed to live up to expectations, while growing market risks kept moves in check in what is shaping up to be a ...